title: From serendipity to design: the evolution of drug development in oncology.
abstract: Although screening of natural products remains the major method of discovering new anticancer drugs, newer techniques of rational drug design, computer-aided drug design, and combinatorial synthesis promise to broaden the scope of compounds available for screening. Recent changes in Food and Drug Administration rules allow for accelerated approval of drugs for treating cancer and other life-threatening illnesses, although the three-phase process of clinical trials remains largely unchanged.
authors.affiliation: Department of Hematology/Oncology, Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: M
authors.initials: M
authors.lastname: Markman
authors.forename: D M
authors.initials: DM
authors.lastname: Peereboom
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D017076:Computer-Aided Design; D017277:Drug Approval; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000138:chemical synthesis; D006801:Humans; D009316:National Institutes of Health (U.S.); D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational